Therapeutic effects of herbal chemicals in traditional Chinese medicine on Alzheimer's disease

Current Medicinal Chemistry

Volumn 22, Issue 19, 2015, Pages 2392-2403

  Cheung, T S ^a   Song, T H ^a   Ng, T B ^b   Wu, F H ^c   Lao, L X ^a   Tang, S C W ^d   Ho, J C M ^d   Zhang, K Y B ^a   Sze, S C W ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alzheimer's disease; Beta amyloid; Therapeutic potential; Traditional Chinese Medicine; secretases; secretases

Indexed keywords

ALPHA SECRETASE; ALPHA SECRETASE INHIBITOR; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE INHIBITOR; BAICALEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; COPTIS CHINENSIS EXTRACT; CRYPTOTANSHINONE; DAVUNETIDE; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HEAT SHOCK PROTEIN; HEME OXYGENASE; HUPERZINE A; MEMANTINE; MITOCHONDRIAL DNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PYRUVATE DEHYDROGENASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RIVASTIGMINE; SALVIANOLIC ACID B; TACRINE; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ALZHEIMER DISEASE; ARTICLE; BLOOD CLOTTING; CELL DIFFERENTIATION; CELL PROLIFERATION; CHINESE HERB; CHINESE MEDICINE; CLINICAL TRIAL (TOPIC); COGNITION; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL (TOPIC); COPTIS CHINENSIS; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; GINSENG; MAGNOLIA OFFICINALIS; MEMORY; MENTAL CAPACITY; MICROBIAL ACTIVITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL; NITROSATIVE STRESS; OXIDATIVE STRESS; PAEONIA LACTIFLORA; PAEONIA LACTIFLORA PALLAS; PHARMACEUTICAL CARE; POLYGALACEAE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; SALVIA MILTIORRHIZA; SALVIA OFFICINALIS; SCUTELLARIA BAICALENSIS GEORGI; TRIPTERYGIUM WILFORDII; WESTERN MEDICINE; ANIMAL; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION;

ALZHEIMER DISEASE; ANIMALS; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL;

EID: 84937132147     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150520095509     Document Type: Article

References (140)

1. Burns, A.; Byrne, E. J.; Maurer, K. Alzheimer's disease. Lancet, 2002, 360, 163-165.
2. Association, A. 2013 Alzheimer's disease facts and figures. Alzheimer's Dement., 2013, 9(2), 208-245.
3. Janssen, J. C.; Beck, J. A.; Campbell, T. A.; Dickinson, A.; Fox, N. C.; Harvey, R. J.; Houlden, H.; Rossor, M. N.; Collinge, J. Early onset familial alzheimer's disease: mutation frequency in 31 Families. Neurology, 2003, 60(2), 235-239.
4. Reisburg, B.E. Franssen, E. H. Clinical stages of alzheimer's disease. The Encyclopedia of Visual Medicine Series, 1999, pp. 11-20.
5. Rochet, J. C.; Lansbury, P. T. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol., 2000, 10(1), 60-68.
6. Lee, V. M.; Goedert, M.; Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci., 2001, 24, 1121-1159.
7. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
8. Haass, C.; Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the alzheimer's amyloid betapeptide. Nat. Rev. Mol. Cell Biol., 2007, 8(2), 101-112.
9. Rosen, D. R.; Martin-Morris, L.; Luo, L. Q.; White, K. A drosophila gene encoding a protein resembling the human betaamyloid protein precursor. Proc. Natl. Acad. Sci. U. S. A., 1989, 86(7), 2478-2482.
10. Nunan, J.; Small, D. H. Regulation of app cleavage by alpha-, betaand gamma-secretases. FEBS Lett., 2000, 483(1), 6-10.
11. Kojro, E.; Fahrenholz, F. The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell. Biochem., 2005, 38, 105-127.
12. Esch, F. S.; Keim, P. S.; Beattie, E. C.; Blacher, R. W.; Culwell, A. R.; Oltersdorf, T.; McClure, D.; Ward, P. J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990, 248 (4959), 1122-1124.
13. Tsukahara, F.; Maru, Y. Identification of novel nuclear export and nuclear localization-related signals in human heat shock cognate protein 70. J. Biol. Chem., 2004, 279(10), 8867-8872.
14. Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory, M. C.; Pauley, A. M.; Brashier, J. R.; Stratman, N. C.; Mathews, W. R.; Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson, R. L.; Gurney, M. E. Membrane-anchored aspartyl protease with alzheimer's disease beta-secretase activity. Nature, 1999, 402(6761), 533-537.
15. Seubert, P.; Oltersdorf, T.; Lee, M. G.; Barbour, R.; Blomquist, C.; Davis, D. L.; Bryant, K.; Fritz, L. C.; Galasko, D.; Thal, L. J. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature, 1993, 361(6409), 260-263.
16. Walsh, D. M.; Selkoe, D. J. A beta oligomers - a decade of discovery. J. Neurochem., 2007, 101(5), 1172-1184.
17. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science, 2002, 298(5594), 789-791.
18. Mungarro-Menchaca, X.; Ferrera, P.; Morán, J.; Arias, C. Betaamyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J. Neurosci. Res., 2002, 68(1), 89-96.
19. Hauptmann, S.; Keil, U.; Scherping, I.; Bonert, A.; Eckert, A.; Müller, W. E. Mitochondrial dysfunction in sporadic and genetic alzheimer's disease. Exp. Gerontol., 2006, 41(7), 668-673.
20. Reddy, P. H.; Beal, M. F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and alzheimer's disease. Trends Mol. Med., 2008, 14(2), 45-53.
21. Oddo, S.; Caccamo, A.; Shepherd, J. D.; Murphy, M. P.; Golde, T. E.; Kayed, R.; Metherate, R.; Mattson, M. P.; Akbari, Y.; LaFerla, F. M. Triple-transgenic model of alzheimer's disease with plaques and tangles: intracellular abeta and synaptic dysfunction. Neuron, 2003, 39(3), 409-421.
22. Lewis, J.; Dickson, D. W.; Lin, W. L.; Chisholm, L.; Corral, A.; Jones, G.; Yen, S. H.; Sahara, N.; Skipper, L.; Yager, D.; Eckman, C.; Hardy, J.; Hutton, M.; McGowan, E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and aPP. Science, 2001, 293(5534), 1487-1491.
23. Lucas, J. J.; Hernández, F.; Gómez-Ramos, P.; Morán, M. A.; Hen, R.; Avila, J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in gsk-3beta conditional transgenic mice. EMBO J., 2001, 20(1-2), 27-39.
24. Arriagada, P. V; Growdon, J. H.; Hedley-Whyte, E. T.; Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of alzheimer's disease. Neurology, 1992, 42(3 Pt 1), 631-639.
25. Götz, J.; Chen, F.; van Dorpe, J.; Nitsch, R. M. Formation of neurofibrillary tangles in p3011 tau transgenic mice induced by abeta 42 fibrils. Science, 2001, 293(5534), 1491-1495.
26. Khlistunova, I.; Biernat, J.; Wang, Y.; Pickhardt, M.; von Bergen, M.; Gazova, Z.; Mandelkow, E.; Mandelkow, E.M. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem., 2006, 281(2), 1205-1214.
27. Santacruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hyman, B.; Hutton, M.; Ashe, K. H. Tau suppression in a neurodegenerative mouse model improves memory function. Science, 2005, 309(5733), 476-481.
28. Oddo, S.; Vasilevko, V.; Caccamo, A.; Kitazawa, M.; Cribbs, D. H.; LaFerla, F. M. Reduction of soluble abeta and tau, but not soluble abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem., 2006, 281(51), 39413-39423.
29. Masliah, E.; Mallory, M.; Alford, M.; DeTeresa, R.; Hansen, L. A.; McKeel, D. W.; Morris, J. C. Altered expression of synaptic proteins occurs early during progression of alzheimer's disease. Neurology, 2001, 56(1), 127-129.
30. DeKosky, S. T.; Scheff, S. W. Synapse loss in frontal cortex biopsies in alzheimer's disease: correlation with cognitive severity. Ann. Neurol., 1990, 27(5), 457-464.
31. Terry, R. D.; Masliah, E.; Salmon, D. P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L. A.; Katzman, R. Physical basis of cognitive alterations in alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30(4), 572-580.
32. Davies, C. A.; Mann, D. M.; Sumpter, P. Q.; Yates, P. O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with alzheimer's disease. J. Neurol. Sci., 1987, 78(2), 151-164.
33. Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med., 2010, 362, 329-344.
34. Wang, H. Y.; Lee, D. H.; D'Andrea, M. R.; Peterson, P. A.; Shank, R. P.; Reitz, A. B. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. implications for alzheimer's disease pathology. J. Biol. Chem., 2000, 275(8), 5626-5632.
35. Hynd, M. R.; Scott, H. L.; Dodd, P. R. Glutamate-mediated excitotoxicity and neurodegeneration in alzheimer's disease. Neurochem. Int., 2004, 45(5), 583-595.
36. LUCAS, D. R.; NEWHOUSE, J. P. The toxic effect of sodium l-glutamate on the inner layers of the retina. amA. Arch. Ophthalmol., 1957, 58(2), 193-201.
37. Butterfield, D. A.; Pocernich, C. B. The glutamatergic system and alzheimer's disease: therapeutic implications. CNS Drugs, 2003, 17(9), 641-652.
38. Caspersen, C.; Wang, N.; Yao, J.; Sosunov, A.; Chen, X.; Lustbader, J. W.; Xu, H. W.; Stern, D.; McKhann, G.; Yan, S. Du. Mitochondrial abeta: a potential focal point for neuronal metabolic dysfunction in alzheimer's disease. FASEB J., 2005, 19(14), 2040-2041.
39. Gibson, G. E.; Sheu, K. F.; Blass, J. P. Abnormalities of mitochondrial enzymes in alzheimer disease. J. Neural Transm., 1998, 105(8-9), 855-870.
40. Sorbi, S.; Bird, E. D.; Blass, J. P. Decreased pyruvate dehydrogenase complex activity in huntington and alzheimer brain. Ann. Neurol., 1983, 13(1), 72-78.
41. Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R. L.; Atwood, C. S.; Johnson, A. B.; Kress, Y.; Vinters, H. V; Tabaton, M.; Shimohama, S.; Cash, A. D.; Siedlak, S. L.; Harris, P. L.; Jones, P. K.; Petersen, R. B.; Perry, G.; Smith, M. A. Mitochondrial abnormalities in alzheimer's disease. J. Neurosci., 2001, 21(9), 3017-3023.
42. Poon, H. F.; Calabrese, V.; Scapagnini, G.; Butterfield, D. A. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontol. A. Biol. Sci. Med. Sci., 2004, 59(5), 478-493.
43. Barone, E.; Di Domenico, F.; Cenini, G.; Sultana, R.; Cini, C.; Preziosi, P.; Perluigi, M.; Mancuso, C.; Butterfield, D. A. Biliverdin reductase - a protein levels and activity in the brains of subjects with alzheimer disease and mild cognitive impairment. Biochim. Biophys. Acta, 2011, 1812(4), 480-487.
44. Barone, E.; Di Domenico, F.; Sultana, R.; Coccia, R.; Mancuso, C.; Perluigi, M.; Butterfield, D. A. Heme oxygenase-1 posttranslational modifications in the brain of subjects with alzheimer disease and mild cognitive impairment. Free Radic. Biol. Med., 52(11-12), 2292-2301.
45. Mattson, M. P.; Partin, J.; Begley, J. G. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res., 1998, 807(1-2), 167-176.
46. Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. R. Copper, iron and zinc in alzheimer's disease senile plaques. J. Neurol. Sci., 1998, 158(1), 47-52.
47. Yamamoto, A.; Shin, R.-W.; Hasegawa, K.; Naiki, H.; Sato, H.; Yoshimasu, F.; Kitamoto, T. Iron (iii) induces aggregation of hyperphosphorylated tau and its reduction to iron (ii) reverses the aggregation: implications in the formation of neurofibrillary tangles of alzheimer's disease. J. Neurochem., 2002, 82(5), 1137-1147.
48. Mancuso, C.; Siciliano, R.; Barone, E.; Butterfield, D. A.; Preziosi, P. Pharmacologists and alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opin. Investig. Drugs, 2011, 20(9), 1243-1261.
49. Watkins, P. B.; Zimmerman, H. J.; Knapp, M. J.; Gracon, S. I.; Lewis, K. W. Hepatotoxic Effects of tacrine administration in patients with alzheimer's disease. JAMA, 1994, 271(13), 992-998.
50. Davis, K. L.; Mohs, R. C.; Marin, D.; Purohit, D. P.; Perl, D. P.; Lantz, M.; Austin, G.; Haroutunian, V. Cholinergic markers in elderly patients with early signs of alzheimer disease. JAMA, 1999, 281(15), 1401-1406.
51. Lipton, S. A. Failures and successes of nmda receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx., 2004, 1(1), 101-110.
52. Imbimbo, B. P.; Peretto, I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of alzheimer's disease. Curr. Opin. Investig. Drugs, 2009, 10(7), 721-730.
53. Galasko, D. R.; Graff-Radford, N.; May, S.; Hendrix, S.; Cottrell, B. A.; Sagi, S. A.; Mather, G.; Laughlin, M.; Zavitz, K. H.; Swabb, E.; Golde, T. E.; Murphy, M. P.; Koo, E. H. Safety, tolerability, pharmacokinetics, and abeta levels after short-term administration of r-flurbiprofen in healthy elderly individuals. Alzheimer Dis. Assoc. Disord., 21(4), 292-299.
54. Wong, G. T.; Manfra, D.; Poulet, F. M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J. S.; Lee, H.-J. J.; Zhang, L.; Higgins, G. A.; Parker, E. M. Chronic treatment with the gamma-secretase inhibitor ly-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem., 2004, 279(13), 12876-12882.
55. Extance, A. Alzheimer's failure raises questions about diseasemodifying strategies. Nat. Rev. Drug Discov., 2010, 9(10), 749-751.
56. Green, R. C.; Schneider, L. S.; Amato, D. A.; Beelen, A. P.; Wilcock, G.; Swabb, E. A.; Zavitz, K. H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild alzheimer disease: a randomized controlled trial. JAMA, 2009, 302(23), 2557-2564.
57. Wisniewski, T.; Goñi, F. Immunotherapeutic approaches for alzheimer's disease. Neuron, 2015, 85, 1162-1176.
58. Doody, R. S.; Thomas, R. G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P. S.; Siemers, E.; Liu-Seifert, H.; Mohs, R. Phase 3 trials of solanezumab for mild-to-moderate alzheimer's disease. N. Engl. J. Med., 2014, 370(4), 311-321.
59. Salloway, S.; Sperling, R.; Fox, N. C.; Blennow, K.; Klunk, W.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Porsteinsson, A. P.; Ferris, S.; Reichert, M.; Ketter, N.; Nejadnik, B.; Guenzler, V.; Miloslavsky, M.; Wang, D.; Lu, Y.; Lull, J.; Tudor, I. C.; Liu, E.; Grundman, M.; Yuen, E.; Black, R.; Brashear, H. R. Two phase 3 trials of bapineuzumab in mild-to-moderate alzheimer's disease. N. Engl. J. Med., 2014, 370(4), 322-333.
60. Matsuoka, Y.; Jouroukhin, Y.; Gray, A. J.; Ma, L.; Hirata-Fukae, C.; Li, H.F.; Feng, L.; Lecanu, L.; Walker, B. R.; Planel, E.; Arancio, O.; Gozes, I.; Aisen, P. S. A neuronal microtubuleinteracting agent, napvsipq, reduces tau pathology and enhances cognitive function in a mouse model of alzheimer's disease. J. Pharmacol. Exp. Ther., 2008, 325(1), 146-153.
61. Wischik, C. M.; Staff, R. T.; Wischik, D. J.; Bentham, P.; Murray, A. D.; Storey, J. M. D.; Kook, K. A.; Harrington, C. R. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate alzheimer's disease. J. Alzheimers. Dis., 2015, 44(2), 705-720.
62. Morimoto, B. H.; Fox, A. W.; Stewart, A. J.; Gold, M. Davunetide: A review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev. Clin. Pharmacol., 2013, 6(5), 483-502.
63. La Fata, G.; Weber, P.; Mohajeri, M. H. Effects of vitamin e on cognitive performance during ageing and in alzheimer's disease. Nutrients, 2014, 6 (12), 5453-5472.
64. Dysken, M. W.; Sano, M.; Asthana, S.; Vertrees, J. E.; Pallaki, M.; Llorente, M.; Love, S.; Schellenberg, G. D.; McCarten, J. R.; Malphurs, J.; Prieto, S.; Chen, P.; Loreck, D. J.; Trapp, G.; Bakshi, R. S.; Mintzer, J. E.; Heidebrink, J. L.; Vidal-Cardona, A.; Arroyo, L. M.; Cruz, A. R.; Zachariah, S.; Kowall, N. W.; Chopra, M. P.; Craft, S.; Thielke, S.; Turvey, C. L.; Woodman, C.; Monnell, K. A.; Gordon, K.; Tomaska, J.; Segal, Y.; Peduzzi, P. N.; Guarino, P. D. Effect of vitamin e and memantine on functional decline in alzheimer disease: the team-ad va cooperative randomized trial. JAMA, 2014, 311(1), 33-44.
65. Lloret, A.; Badía, M.-C.; Mora, N. J.; Pallardó, F. V; Alonso, M.- D.; Viña, J. Vitamin e paradox in alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimers. Dis., 2009, 17(1), 143-149.
66. Pan, S.Y.; Chen, S.B.; Dong, H.G.; Yu, Z.L.; Dong, J.C.; Long, Z.X.; Fong, W.F.; Han, Y.F.; Ko, K.M. New perspectives on chinese herbal medicine (zhong-yao) research and development. Evid. Based. Complement. Alternat. Med., 2011, 2011, 403709.
67. Russo, P.; Frustaci, A.; Del Bufalo, A.; Fini, M.; Cesario, A. from traditional european medicine to discovery of new drug candidates for the treatment of dementia and alzheimer's disease: acetylcholinesterase inhibitors. Curr. Med. Chem, 2013, 20(8), 976-983.
68. Pocernich, C. B.; Lange, M. L. B.; Sultana, R.; Butterfield, D. A. Nutritional approaches to modulate oxidative stress in alzheimer's disease. Curr. Alzheimer Res., 2011, 8(5), 452-469.
69. Wu, W.; Wang, Y. Pharmacological actions and therapeutic applications of salvia miltiorrhiza depside salt and its active components. Acta Pharmacol. Sin., 2012, 33(9), 1119-1130.
70. Kim, D. H.; Jeon, S. J.; Jung, J. W.; Lee, S.; Yoon, B. H.; Shin, B. Y.; Son, K. H.; Cheong, J. H.; Kim, Y. S.; Kang, S. S.; Ko, K. H.; Ryu, J. H. Tanshinone congeners improve memory impairments induced by scopolamine on passive avoidance tasks in mice. Eur. J. Pharmacol., 2007, 574(2-3), 140-147.
71. Mei, Z.; Zhang, F.; Tao, L.; Zheng, W.; Cao, Y.; Wang, Z.; Tang, S.; Le, K.; Chen, S.; Pi, R.; Liu, P. Cryptotanshinone, a compound from salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci. Lett.,2009, 452(2), 90-95.
72. Clostre, F. Ginkgo biloba extract (egb 761). state of knowledge in the dawn of the year 2000. Ann. Pharm. françaises, 1999, 57(Suppl 1), 1S8-S88.
73. Ho, Y.S.; So, K.F.; Chang, R. C.C. Drug Discovery from chinese medicine against neurodegeneration in alzheimer's and vascular dementia. Chin. Med., 2011, 6, 15.
74. Topic, B.; Tani, F.; Tsiakitzis, K.; Kourounakis, P. N.; Dere, E.; Hasenöhrl, R. U.; Ha¨cker, R.; Mattern, C. M.; Huston, J. P. Enhanced maze performance and reduced oxidative stress by combined extracts of zingiber officinale and ginkgo biloba in the aged rat. Neurobiol. Aging, 23(1), 135-143.
75. Bastianetto, S.; Ramassamy, C.; Doré, S.; Christen, Y.; Poirier, J.; Quirion, R. The ginkgo biloba extract (egb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci., 2000, 12(6), 1882-1890.
76. Yao, Z.; Drieu, K.; Papadopoulos, V. The Ginkgo biloba extract egb 761 rescues the pc12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res., 2001, 889(1-2), 181-190.
77. Stoll, S.; Scheuer, K.; Pohl, O.; Müller, W. E. Ginkgo biloba extract (egb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry, 1996, 29(4), 144-149.
78. Colciaghi, F.; Borroni, B.; Zimmermann, M.; Bellone, C.; Longhi, A.; Padovani, A.; Cattabeni, F.; Christen, Y.; Di Luca, M. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by ginkgo biloba extracts. Neurobiol. Dis., 2004, 16(2), 454-460.
79. Augustin, S.; Rimbach, G.; Augustin, K.; Cermak, R.; Wolffram, S. Gene regulatory effects of ginkgo biloba extract and its flavonol and terpenelactone fractions in mouse brain. J. Clin. Biochem. Nutr., 2009, 45(3), 315-321.
80. Maurer, K.; Ihl, R.; Dierks, T.; Frölich, L. Clinical efficacy of ginkgo biloba special extract egb 761 in dementia of the alzheimer type. J. Psychiatr. Res., 31(6), 645-655.
81. Schneider, L. S.; DeKosky, S. T.; Farlow, M. R.; Tariot, P. N.; Hoerr, R.; Kieser, M. A randomized, double-blind, placebocontrolled trial of two doses of ginkgo biloba extract in dementia of the alzheimer's type. Curr. Alzheimer Res., 2005, 2(5), 541-551.
82. Mazza, M.; Capuano, A.; Bria, P.; Mazza, S. Ginkgo biloba and donepezil: a comparison in the treatment of alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol., 2006, 13(9), 981-985.
83. Hsieh, M. T.; Peng, W. H.; Wu, C. R.; Wang, W. H. The Ameliorating effects of the cognitive-enhancing chinese herbs on scopolamine-induced amnesia in rats. Phytother. Res., 2000, 14(5), 375-377.
84. Hsieh, Y.S.; Kuo, W.H.; Lin, T.W.; Chang, H.-R.; Lin, T.H.; Chen, P.N.; Chu, S.C. Protective effects of berberine against low-density lipoprotein (ldl) oxidation and oxidized ldl-induced cytotoxicity on endothelial cells. J. Agric. Food Chem., 2007, 55(25), 10437-10445.
85. Racková, L.; Májeková, M.; Kost'álová, D.; Stefek, M. Antiradical and antioxidant activities of alkaloids isolated from mahonia aquifolium. structural aspects. Bioorg. Med. Chem., 2004, 12(17), 4709-4715.
86. Jung, H. A.; Min, B.-S.; Yokozawa, T.; Lee, J.H.; Kim, Y. S.; Choi, J. S. Anti-alzheimer and antioxidant activities of coptidis rhizoma alkaloids. Biol. Pharm. Bull, 2009, 32(8), 1433-1438.
87. Choi, J. G.; Kim, H. G.; Kim, M. C.; Yang, W. M.; Huh, Y.; Kim, S. Y.; Oh, M. S. Polygalae radix inhibits toxin-induced neuronal death in the parkinson's disease models. J. Ethnopharmacol., 2011, 134 (2), 414-421.
88. Inoue, E.; Shimizu, Y.; Shoji, M.; Tsuchida, H.; Sano, Y.; Ito, C. Pharmacological properties of n-095, a drug containing red ginseng, polygala root, saffron, antelope horn and aloe wood. Am. J. Chin. Med., 2005, 33(1), 49-60.
89. Jia, H.; Jiang, Y.; Ruan, Y.; Zhang, Y.; Ma, X.; Zhang, J.; Beyreuther, K.; Tu, P.; Zhang, D. Tenuigenin treatment decreases secretion of the alzheimer's disease amyloid beta-protein in cultured cells. Neurosci. Lett, 2004, 367(1), 123-128.
90. Lv, J.; Jia, H.; Jiang, Y.; Ruan, Y.; Liu, Z.; Yue, W.; Beyreuther, K.; Tu, P.; Zhang, D. Tenuifolin, an extract derived from tenuigenin, inhibits amyloid-β secretion in vitro. Acta Physiol., 2009, 196, 419-425.
91. Barrow, C. J.; Zagorski, M. G. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science, 1991, 253(5016), 179-182.
92. Takashima, A.; Honda, T.; Yasutake, K.; Michel, G.; Murayama, O.; Murayama, M.; Ishiguro, K.; Yamaguchi, H. Activation of tau protein kinase i/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res., 1998, 31(4), 317-323.
93. Wirths, O.; Multhaup, G.; Bayer, T. A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade. J. Neurochem., 2004, 91(3), 513-520.
94. Chou, T.C. Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia. Br. J. Pharmacol., 2003, 139(6), 1146-1152.
95. Fujiwara, H.; Tabuchi, M.; Yamaguchi, T.; Iwasaki, K.; Furukawa, K.; Sekiguchi, K.; Ikarashi, Y.; Kudo, Y.; Higuchi, M.; Saido, T. C.; Maeda, S.; Takashima, A.; Hara, M.; Yaegashi, N.; Kase, Y.; Arai, H. A Traditional medicinal herb paeonia suffruticosa and its active constituent 1,2,3,4,6-penta-o-galloyl-β-d-glucopyranose have potent anti-aggregation effects on alzheimer's amyloid βproteins in vitro and in vivo. J. Neurochem., 2009, 109, 1648-1657.
96. Lu, J.H.; Ardah, M. T.; Durairajan, S. S. K.; Liu, L.F.; Xie, L.X.; Fong, W.F. D.; Hasan, M. Y.; Huang, J.D.; El-Agnaf, O. M. A.; Li, M. Baicalein inhibits formation of α -synuclein oligomers within living cells and prevents aβ peptide fibrillation and oligomerisation. Chembiochem., 2011, 12(4), 615-624.
97. Jiang, R.-W.; Lau, K.-M.; Hon, P.-M.; Mak, T. C. W.; Woo, K.-S.; Fung, K.-P. Chemistry and biological activities of caffeic acid derivatives from salvia miltiorrhiza. Curr. Med. Chem. 2005, 12 (2), 237-246.
98. Lin, Y.H.; Liu, A.H.; Wu, H.L.; Westenbroek, C.; Song, Q.L.; Yu, H.M.; Ter Horst, G. J.; Li, X.J. Salvianolic acid b, an antioxidant from salvia miltiorrhiza, prevents abeta(25-35)-induced reduction in bprp in pC12 Cells. Biochem. Biophys. Res. Commun., 2006, 348(2), 593-599.
99. Durairajan, S. S. K.; Yuan, Q.; Xie, L.; Chan, W. S.; Kum, W. F.; Koo, I.; Liu, C.; Song, Y.; Huang, J. D.; Klein, W. L.; Li, M. Salvianolic Acid B Inhibits aβ fibril formation and disaggregates preformed fibrils and protects against aβ-induced cytotoxicty. Neurochem. Int., 2008, 52, 741-750.
100. Fujiwara, H.; Iwasaki, K.; Furukawa, K.; Seki, T.; He, M.; Maruyama, M.; Tomita, N.; Kudo, Y.; Higuchi, M.; Saido, T. C.; Maeda, S.; Takashima, A.; Hara, M.; Ohizumi, Y.; Arai, H. Uncaria rhynchophylla, a chinese medicinal herb, has potent antiaggregation effects on alzheimer's beta-amyloid proteins. J. Neurosci. Res, 2006, 84(2), 427-433.
101. Radad, K.; Gille, G.; Liu, L.; Rausch, W.-D. Use of ginseng in medicine with emphasis on neurodegenerative disorders. J. Pharmacol. Sci. 2006, 100 (3), 175-186.
102. Deng, H. L.; Zhang, J. T. Anti-Lipid Peroxilative Effect of Ginsenoside Rb1 and Rg1. Chin. Med. J. (Engl). 1991, 104(5), 395-398.
103. Liu, M.; Zhang, J. T. Protective effects of ginsenoside rb1 and rg1 on cultured hippocampal neurons. Yao Xue Xue Bao, 1995, 30(9), 674-678.
104. Kim, Y. C.; Kim, S. R.; Markelonis, G. J.; Oh, T. H. Ginsenosides rb1 and rg3 protect cultured rat cortical cells from glutamateinduced neurodegeneration. J. Neurosci. Res., 1998, 53(4), 426-432.
105. Ji, Z. N.; Dong, T. T. X.; Ye, W. C.; Choi, R. C.; Lo, C. K.; Tsim, K. W. K. Ginsenoside re attenuate beta-amyloid and serum-free induced neurotoxicity in pc12 cells. J. Ethnopharmacol., 2006, 107(1), 48-52.
106. Li, N.; Liu, B.; Dluzen, D. E.; Jin, Y. Protective effects of ginsenoside rg2 against glutamate-induced neurotoxicity in pc12 cells. J. Ethnopharmacol., 2007, 111(3), 458-463.
107. Sha, D.; Li, L.; Ye, L.; Liu, R.; Xu, Y. Icariin inhibits neurotoxicity of beta-amyloid by upregulating cocaine-regulated and amphetamine-regulated transcripts. Neuroreport, 2009, 20(17), 1564-1567.
108. Li, L.; Tsai, H.-J.; Li, L.; Wang, X.M. Icariin inhibits the increased inward calcium currents induced by amyloid-beta(25-35) peptide in ca1 pyramidal neurons of neonatal rat hippocampal slice. Am. J. Chin. Med., 2010, 38(1), 113-125.
109. Shi, C.; Zhao, L.; Zhu, B.; Li, Q.; Yew, D. T.; Yao, Z.; Xu, J. Protective effects of ginkgo biloba extract (egb761) and its constituents quercetin and ginkgolide b against beta-amyloid peptide-induced toxicity in sh-sy5Y Cells. Chem. Biol. Interact., 2009, 181(1), 115-123.
110. Lee, J. W.; Lee, Y. K.; Lee, B. J.; Nam, S.Y.; Lee, S. Il; Kim, Y. H.; Kim, K. H.; Oh, K.W.; Hong, J. T. Inhibitory effect of ethanol extract of magnolia officinalis and 4-o-methylhonokiol on memory impairment and neuronal toxicity induced by beta-amyloid. Pharmacol. Biochem. Behav., 2010, 95(1), 31-40.
111. Zhang, J.; Cheng, Y.; Zhang, J.T. Protective effect of (-) clausenamide against neurotoxicity induced by okadaic acid and beta-amyloid peptide 25-35. Yao Xue Xue Bao, 2007, 42(9), 935-942.
112. Cummings, J. L.; Vinters, H. V; Cole, G. M.; Khachaturian, Z. S. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology, 1998, 51(1 Suppl 1), S2-S17; discussion S65-S67.
113. Smith, W. W.; Gorospe, M.; Kusiak, J. W. Signaling mechanisms underlying abeta toxicity: potential therapeutic targets for alzheimer's disease. CNS Neurol. Disord. Drug Targets, 2006, 5(3), 355-361.
114. Paresce, D. M.; Ghosh, R. N.; Maxfield, F. R. Microglial cells internalize aggregates of the alzheimer's disease amyloid betaprotein via a scavenger receptor. Neuron, 1996, 17(3), 553-565.
115. Nicoll, J. A. R.; Weller, R. O. A new role for astrocytes: betaamyloid homeostasis and degradation. Trends Mol. Med., 2003, 9(7), 281-282.
116. Wyss-Coray, T.; Mucke, L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron, 2002, 35(3), 419-432.
117. Yan, S. D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A. M. Rage and amyloid-beta peptide neurotoxicity in alzheimer's disease. Nature, 1996, 382(6593), 685-691.
118. Li, Y.; Liu, L.; Barger, S. W.; Griffin, W. S. T. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38- mapk pathway. J. Neurosci., 2003, 23(5), 1605-1611.
119. Park, J.-S.; Park, E.-M.; Kim, D.-H.; Jung, K.; Jung, J.-S.; Lee, E.- J.; Hyun, J.-W.; Kang, J. L.; Kim, H.S. Anti-inflammatory mechanism of ginseng saponins in activated microglia. J. Neuroimmunol., 2009, 209 (1-2), 40-49.
120. Kim, H.; Kim, Y. S.; Kim, S. Y.; Suk, K. The plant flavonoid wogonin suppresses death of activated c6 rat glial cells by inhibiting nitric oxide production. Neurosci. Lett., 2001, 309 (1), 67-71.
121. Lee, H.; Kim, Y. O.; Kim, H.; Kim, S. Y.; Noh, H. S.; Kang, S. S.; Cho, G. J.; Choi, W. S.; Suk, K. Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J., 2003, 17(13), 1943-1944.
122. Li, F.Q.; Wang, T.; Pei, Z.; Liu, B.; Hong, J.S. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. J. Neural Transm., 2005, 112(3), 331-347.
123. Suk, K.; Lee, H.; Kang, S. S.; Cho, G. J.; Choi, W. S. Flavonoid baicalein attenuates activation-induced cell death of brain microglia. J. Pharmacol. Exp. Ther., 2003, 305(2), 638-645.
124. Qiu, D.; Kao, P. N. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the chinese medicinal herb tripterygium wilfordii hook. f. Drugs R. D., 2003, 4(1), 1-18.
125. Zhou, H.F.; Liu, X.Y.; Niu, D.B.; Li, F.Q.; He, Q.H.; Wang, X.M. Triptolide Protects dopaminergic neurons from inflammationmediated damage induced by lipopolysaccharide intranigral injection. Neurobiol. Dis., 2005, 18 (3), 441-449.
126. Gong, Y.; Xue, B.; Jiao, J.; Jing, L.; Wang, X. Triptolide inhibits cox-2 expression and pge2 release by suppressing the activity of nfkappab and jnk in lps-treated microglia. J. Neurochem., 2008, 107(3), 779-788.
127. Lleó, A.; Greenberg, S. M.; Growdon, J. H. Current pharmacotherapy for alzheimer's Disease. Annu. Rev. Med., 2006, 57, 513-533.
128. Liu, J.S.; Zhu, Y.L.; Yu, C.M.; Zhou, Y.Z.; Han, Y.Y.; Wu, F.W.; Qi, B.F. The structures of huperzine a and b, two new alkaloids exhibiting marked anticholinesterase activity. Can. J. Chem., 1986, 64(lc), 837-839.
129. Ortega, M. G.; Agnese, A. M.; Cabrera, J. L. Anticholinesterase activity in an alkaloid extract of huperzia saururus. Phytomedicine, 2004, 11(6), 539-543.
130. Zhao, Q.; Tang, X. C. Effects of huperzine a on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur. J. Pharmacol., 2002, 455(2-3), 101-107.
131. Ashani, Y.; Peggins, J. O.; Doctor, B. P. Mechanism of Inhibition of Cholinesterases by Huperzine A. Biochem. Biophys. Res. Commun., 1992, 184(2), 719-726.
132. Saxena, A.; Qian, N.; Kovach, I. M.; Kozikowski, A. P.; Pang, Y. P.; Vellom, D. C.; Radić, Z.; Quinn, D.; Taylor, P.; Doctor, B. P. Identification of amino acid residues involved in the binding of huperzine a to cholinesterases. Protein Sci., 1994, 3(10), 1770-1778.
133. Yue, P.; Tao, T.; Zhao, Y.; Ren, J.; Chai, X. Huperzine a in rat plasma and csf following intranasal administration. Int. J. Pharm., 2007, 337(1-2), 127-132.
134. Chu, D.; Liu, W.; Li, Y.; Li, P.; Gu, J.; Liu, K. Pharmacokinetics of huperzine a in dogs following single intravenous and oral administrations. Planta Med., 2006, 72(6), 552-555.
135. Wang, Q.; Chen, G. Pharmacokinetic behavior of huperzine a in plasma and cerebrospinal fluid after intranasal administration in rats. Biopharm. Drug Dispos., 2009, 30(9), 551-555.
136. Xiao, X. Q.; Wang, R.; Han, Y. F.; Tang, X. C. Protective effects of huperzine a on beta-amyloid(25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci. Lett., 2000, 286(3), 155-158.
137. Wang, R.; Zhang, H. Y.; Tang, X. C. Huperzine a attenuates cognitive dysfunction and neuronal degeneration caused by betaamyloid protein-(1-40) in rat. Eur. J. Pharmacol. 2001, 421(3), 149-156.
138. Yang, G.; Wang, Y.; Tian, J.; Liu, J.P. Huperzine a for alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One, 2013, 8(9), e74916.
139. Wang, R.; Tang, X. C. Neuroprotective effects of huperzine a. Neurosignals, 2005, 14(1-2), 71-82.
140. Pan, S.Y.; Zhou, S.F.; Gao, S.H.; Yu, Z.L.; Zhang, S.F.; Tang, M.K.; Sun, J.N.; Ma, D.L.; Han, Y.F.; Fong, W.F.; Ko, K.M. New perspectives on how to discover drugs from herbal medicines: cam's outstanding contribution to modern therapeutics. Evid. Based Complement Alternat. Med. 2013, 2013, 627375.